All
Following up: PMMA filler shows five-year safety, efficacy
June 1st 2008A retrospective five-year safety and efficacy study of a new PMMA filler shows a low risk of adverse events and a trend toward continued improvement over the entire five-year follow-up period, says a researcher involved with the study.
Depigmenting agents for melasma: Prescription, nonprescription options exist
June 1st 2008Dermatologists commonly turn to a variety of depigmenting agents and therapies for the treatment of melasma and post-inflammatory hyperpigmentation after acne, or traumatic scars and burns, according to Helen M. Torok, M.D., Medical Director, Trillium Creek Dermatology & Surgery, in Medina, Ohio.
Triggering nephrogenic systemic fibrosis: Research looks at role of gadolinium
June 1st 2008Results from accumulating research suggest that gadolinium is a trigger for nephrogenic systemic fibrosis (NSF). Gadolinium exposure occurs through use of gadolinium-containing contrast agent (GCCA), and the type of GCCA may influence NSF risk. Further evidence is needed to verify these theories.
Parsing psoriasis: Common DNA variations increase risk of developing skin condition
June 1st 2008Seven newly identified sites of common DNA variations increase the risk for psoriasis and psoriatic arthritis. The whole genome association study of more than 300,000 single nucleotide polymorphisms (SNPs) was published in the March issue of PLoS Genetics. The goal was to identify new genes and new pathways for drug development.
Botox impacts brain? Italian animal study raises safety concerns about botulinum toxin
June 1st 2008A recent animal study has shown that botulinum toxin injections can travel through retrograde axonal transport to unintended sites, including those in the brain, according to researchers at the Italian National Research Council's Istituto di Neuroscienze.
Opinion: SPF debate: FDA revamps sunscreen safety labeling
June 1st 2008The Food and Drug Administration has been revamping sunscreen safety labeling since the implementation of the final monograph was delayed in 2002. Last August, the FDA issued proposed guidelines for the product labels, with a comment period open until November, 2007. The deadline for comment was extended until late December, and as of May first no new guidelines had been announced.
New study verifies value of CSE - with or without dermoscopy
May 6th 2008Graz, Austria - Though complete skin examination (CSE) by dermoscopy takes longer to conduct than CSE alone when screening for skin cancer, physicians should consider three-minute screening for the disease with either method, according to the results of a study reported by MedScape Today.
Study links high IL-12 levels, increased melanoma mortality
May 6th 2008Houston - Data from a large cohort study shows that an elevated level of interleukin-12 is associated with a significantly increased mortality risk in patients with stage III melanoma with regional metastasis, according to MedPageToday.
Enbrel yields striking improvement in kids
May 1st 2008A phase 3 double-blind, placebo-controlled study shows remarkable efficacy of etanercept for treating pediatric psoriasis, bettering even those results observed in adults. The findings could help pave the way for Food and Drug Administration approval of the biologic, which could change the face of systemic treatment of psoriasis in children.
Psoriasis: New biologics coming closer to market
May 1st 2008Newer biologics to treat psoriasis are currently in late stages of development, and promising data from phase 2 and phase 3 clinical trials should give patients reason to hope. The biologics may be available as early as the end of 2008 or during 2009.